Literature DB >> 2014359

Airflow limitation in sarcoidosis--a study of pulmonary function in 107 patients with newly diagnosed disease.

B D Harrison1, J M Shaylor, T C Stokes, A R Wilkes.   

Abstract

One hundred and seven patients with sarcoidosis attended for pulmonary function testing within 2 weeks of diagnosis. In four Stage 0, 42 Stage I, 32 Stage II, 26 Stage III and three Stage IV patients physiological abnormalities increased with increasing stage. The commonest abnormality, airflow limitation, occurred in 61 patients; a low transfer factor occurred in 29; a restrictive defect, the least common abnormality, occurred in seven. Fifty-nine patients and 30 of those with evidence of airways obstruction never smoked. None of the 52 patients with airflow limitation tested after bronchodilator inhalation demonstrated significant reversibility. All patients with obstruction had evidence of small airways narrowing. The majority had an FEV1/FVC ratio below 75%. Fourteen patients also had a low peak expiratory flow indicative of large airway narrowing. Airflow limitation occurs in all stages of sarcoidosis and should always be looked for in patients with sarcoidosis who have respiratory symptoms.

Entities:  

Mesh:

Year:  1991        PMID: 2014359     DOI: 10.1016/s0954-6111(06)80211-8

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  13 in total

Review 1.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

Review 2.  A concise review of pulmonary sarcoidosis.

Authors:  Robert P Baughman; Daniel A Culver; Marc A Judson
Journal:  Am J Respir Crit Care Med       Date:  2010-10-29       Impact factor: 21.405

3.  Clinical and Biological Insights from the University of California San Francisco Prospective and Longitudinal Cohort.

Authors:  Bryan S Benn; Zoe Lehman; Sharon A Kidd; Melissa Ho; Sara Sun; Joris Ramstein; Nicholas K Arger; Christine P Nguyen; Robert Su; Antonio Gomez; Jeffrey M Gelfand; Laura L Koth
Journal:  Lung       Date:  2017-07-13       Impact factor: 2.584

4.  British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.

Authors:  G J Gibson; R J Prescott; M F Muers; W G Middleton; D N Mitchell; C K Connolly; B D Harrison
Journal:  Thorax       Date:  1996-03       Impact factor: 9.139

5.  Comparison between cardiopulmonary exercise testing parameters and computed tomography findings in patients with thoracic sarcoidosis.

Authors:  Agnaldo José Lopes; Sara Lucia Silveira de Menezes; Cristina Márcia Dias; Juliana Flávia de Oliveira; Míriam Raquel Meira Mainenti; Fernando Silva Guimarães
Journal:  Lung       Date:  2011-08-20       Impact factor: 2.584

6.  Ventilatory disturbances in patients with intrathoracic sarcoidosis - a study from a functional and histological perspective.

Authors:  Diana Calaras; Oxana Munteanu; Valentina Scaletchi; I Simionica; V Botnaru
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

7.  The six-minute walk test in patients with pulmonary sarcoidosis.

Authors:  Esam H Alhamad
Journal:  Ann Thorac Med       Date:  2009-04       Impact factor: 2.219

8.  Refractory pulmonary sarcoidosis - proposal of a definition and recommendations for the diagnostic and therapeutic approach.

Authors:  Peter Korsten; Katharina Strohmayer; Robert P Baughman; Nadera J Sweiss
Journal:  Clin Pulm Med       Date:  2016-03

Review 9.  Obstructive sarcoidosis.

Authors:  Petey Laohaburanakit; Andrew Chan
Journal:  Clin Rev Allergy Immunol       Date:  2003-10       Impact factor: 8.667

10.  Methotrexate treatment efficacy in sarcoidosis might be related to TNF-α polymorphism: real life preliminary study.

Authors:  Anna Goljan Geremek; Elzbieta Puscinska; Monika Czystowska; Agnieszka Skoczylas; Michal Bednarek; Adam Nowinski; Dorota Gorecka; Urszula Demkow; Pawel Sliwinski
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.